| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Acard technology is a Placentia, CA-based company in the Software and Internet sector.
pymetrics leverages behavioral science and audited AI technology to help enterprise companies build diverse teams of top performers, entirely bias free.
A communication technology solutions provider for over 27 years. Offering advanced technologies that help your business connect, communicate, and stay secure.
Map Your Show (MYS) partners with events of all sizes to provide online directories and floor plans, manage booth space, build mobile apps and more